Gender, hormone therapy, and HIV: what should cardiologists know?

Claudia Martinez, R. R. Rikhi

Research output: Contribution to journalReview article

Abstract

Transgender individuals represent the fastest growing minority in the United States and are disproportionately affected by HIV. Hormone therapy is the most common treatment for gender dysphoria in transgender individuals. As HIV is an independent risk factor for coronary artery disease, it is critical to further research the influence masculinising and feminising hormone therapies have on cardiovascular disease. There is a clinical need for evidence-based guidelines for cardiologists to follow to effectively care for and treat transgender patients. For this to be done, the interplay between HIV, hormone therapy, and cardiovascular disease must be better understood through collaboration between researchers and clinicians to achieve maximum benefit from recent advancements.

Original languageEnglish (US)
Pages (from-to)233-236
Number of pages4
JournalNetherlands Heart Journal
Volume27
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Transgender Persons
HIV
Hormones
Cardiovascular Diseases
Therapeutics
Coronary Artery Disease
Research Personnel
Guidelines
Cardiologists
Research

Keywords

  • Cardiovascular disease
  • HIV
  • Hormone replacement therapy
  • Transgender persons

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gender, hormone therapy, and HIV : what should cardiologists know? / Martinez, Claudia; Rikhi, R. R.

In: Netherlands Heart Journal, Vol. 27, No. 5, 01.05.2019, p. 233-236.

Research output: Contribution to journalReview article

@article{b6f74df87e534c558edfe524409aa686,
title = "Gender, hormone therapy, and HIV: what should cardiologists know?",
abstract = "Transgender individuals represent the fastest growing minority in the United States and are disproportionately affected by HIV. Hormone therapy is the most common treatment for gender dysphoria in transgender individuals. As HIV is an independent risk factor for coronary artery disease, it is critical to further research the influence masculinising and feminising hormone therapies have on cardiovascular disease. There is a clinical need for evidence-based guidelines for cardiologists to follow to effectively care for and treat transgender patients. For this to be done, the interplay between HIV, hormone therapy, and cardiovascular disease must be better understood through collaboration between researchers and clinicians to achieve maximum benefit from recent advancements.",
keywords = "Cardiovascular disease, HIV, Hormone replacement therapy, Transgender persons",
author = "Claudia Martinez and Rikhi, {R. R.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1007/s12471-019-1233-6",
language = "English (US)",
volume = "27",
pages = "233--236",
journal = "Netherlands Heart Journal",
issn = "1568-5888",
publisher = "Bohn Stafleu van Loghum",
number = "5",

}

TY - JOUR

T1 - Gender, hormone therapy, and HIV

T2 - what should cardiologists know?

AU - Martinez, Claudia

AU - Rikhi, R. R.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Transgender individuals represent the fastest growing minority in the United States and are disproportionately affected by HIV. Hormone therapy is the most common treatment for gender dysphoria in transgender individuals. As HIV is an independent risk factor for coronary artery disease, it is critical to further research the influence masculinising and feminising hormone therapies have on cardiovascular disease. There is a clinical need for evidence-based guidelines for cardiologists to follow to effectively care for and treat transgender patients. For this to be done, the interplay between HIV, hormone therapy, and cardiovascular disease must be better understood through collaboration between researchers and clinicians to achieve maximum benefit from recent advancements.

AB - Transgender individuals represent the fastest growing minority in the United States and are disproportionately affected by HIV. Hormone therapy is the most common treatment for gender dysphoria in transgender individuals. As HIV is an independent risk factor for coronary artery disease, it is critical to further research the influence masculinising and feminising hormone therapies have on cardiovascular disease. There is a clinical need for evidence-based guidelines for cardiologists to follow to effectively care for and treat transgender patients. For this to be done, the interplay between HIV, hormone therapy, and cardiovascular disease must be better understood through collaboration between researchers and clinicians to achieve maximum benefit from recent advancements.

KW - Cardiovascular disease

KW - HIV

KW - Hormone replacement therapy

KW - Transgender persons

UR - http://www.scopus.com/inward/record.url?scp=85064532926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064532926&partnerID=8YFLogxK

U2 - 10.1007/s12471-019-1233-6

DO - 10.1007/s12471-019-1233-6

M3 - Review article

AN - SCOPUS:85064532926

VL - 27

SP - 233

EP - 236

JO - Netherlands Heart Journal

JF - Netherlands Heart Journal

SN - 1568-5888

IS - 5

ER -